Form 8-K Axsome Therapeutics, For: Aug 23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Cowen Maintains Positive View on Axsome Therapeutics (AXSM) Despite PDUFA Delay
August 23, 2021 12:58 PM EDTCowen analyst Joseph Thome reiterated an Outperform rating and $125.00 price target on Axsome Therapeutics (NASDAQ: AXSM) after the FDA informed the company last Friday that the Agency would not complete the review of the NDA submission regarding AXS-05 in MDD by the target PDUFA... More
